Pearland, TX – Lonza is opening the world’s largest dedicated cell-and-gene-therapy facility, built in anticipation of rising demand from developers of cell and gene therapies – the next era in medicine – and with the mission of enabling them to deliver these types of treatments to patients around the world more quickly and efficiently.
The 300,000-foot-facility located in the greater Houston area offers a state-of-the-art, fully integrated, everything-under-one-roof access to some of the world’s most innovative cell-and-gene-therapy manufacturing technologies.
“Lonza Houston will serve as a center of excellence for cell-and-gene-therapy process development from concept through pre-clinical, clinical and commercialization, all the way to the patient,” said Andreas Weiler, Business Unit head for Emerging Technologies at Lonza Pharma & Biotech, in a statement preceding the opening ceremony. “This facility has the potential to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases, under one roof. It will set a new standard in biopharmaceutical manufacturing and stand as one of four centers of excellence in cell and gene therapy in the only global network spanning three continents.”
The Lonza Houston Center of Excellence is already operational and manufacturing for several customers. This facility is recruiting employees and will have more than 200 full-time staff including scientists, engineers, MBAs and biotechnology professionals by the end of 2018 and continue to recruit high-value positions as market demand increases.
“Lonza is committed to the evolution and cultivation of a diverse medical and life-science community in the Greater Houston area for many years to come,” says Marc Funk, Lonza Pharma & Biotech COO. “The site is well-positioned to meet the demands of the growing cell-and-gene-therapy field. Combining this leading-edge facility with our unmatched experience and expertise in cell and gene therapy will allow us to provide a key advantage to biopharmaceutical companies and academic researchers and ultimately to the patients they serve.”